U.S. Colorectal Cancer Screening Market to Witness Considerable Growth through 2027

The U.S. colorectal cancer screening market is projected to undergo noteworthy expansion owing to rising colorectal cancer instances and growing geriatric population. Colorectal cancer commences in the colon or the rectum. It is among the most common cancer types diagnosed in the United States and can be prevented through screening tests that detect precancerous polyps, consequently allowing for their removal before they become cancerous. There are various screening tests accessible for colorectal cancer encompassing fecal immunochemical tests (FIT), fecal occult blood tests (FOBT), flexible sigmoidoscopy, colonoscopy, CT colonography, and endoscopy.

U.S. colorectal cancer screening market size was valued at US$ 5.95 Bn in 2023 and is expected to reach US$ 10.62 Bn by 2031, grow at a compound annual growth rate (CAGR) of 7.5% from 2024 to 2031.

Key Takeaways
Key players operating in the U.S. colorectal cancer screening market are Abbott Laboratories, Alere Inc., Clinical Genomics Pty Ltd., EDP Biotech Corporation, Epigenomics AG, Novigenix SA, Quest Diagnostics, and Quidel Corporation.
The rising initiation of colorectal cancer screening programs by governments and private organizations provide lucrative opportunities for market players. Furthermore, development of advanced non-invasive screening techniques to increase patient compliance for screening also presents growth prospects.

Geographical expansion into emerging countries in Latin America and Asia Pacific will allow key players to tap into fast growing markets and strengthen their global presence.

Market Drivers
Increasing incidence of U.S. Colorectal Cancer Screening Market is a major factor driving the demand for screening tests in the country. According to estimates, around 150,000 new cases of colorectal cancer are diagnosed annually in the U.S. Early detection through screening can significantly improve treatment outcomes.

Market Restrains
Despite guidelines recommending regular screening from age 50, actual screening rates remain below target levels due to low awareness and reluctance for invasive tests. Cost concerns over costly screening tests also restrain market growth to some extent.

Segment Analysis
The U.S. colorectal cancer screening market is segmented into colonoscopy, fecal occult blood test, flexible sigmoidoscopy, biopsy, CTC, and others. Among these, colonoscopy accounts for the largest market share as it is considered as the gold standard test for colorectal cancer screening. Colonoscopy allows direct visualization of the entire colon and rectum along with tissue and polyp sampling, if detected. This makes it highly efficient in detecting colorectal cancer at an early stage and removing precancerous polyps, thereby dominating the market.

Flexible sigmoidoscopy is expected to grow at a significant rate during the forecast period. This is because sigmoidoscopy requires less preparation as compared to colonoscopy and has fewer risks associated with the procedure. Also, it is more affordable and accessible than colonoscopy, making it an attractive option for colorectal cancer screening.

Global Analysis
North America dominates the global colorectal cancer screening market and is estimated to continue its dominance during the forecast period. This is attributed to the increasing acceptance of sensitive screening tests such as colonoscopy and rising awareness regarding early detection of colorectal cancer in the region. The market in the Asia Pacific is anticipated to grow at the fastest rate owing to improving healthcare infrastructure, rising healthcare expenditure, increasing disposable incomes, and growing population.

Get This Report in Japanese Language: 米国大腸がん検査市場

Get This Report in Korean Language: 미국 대장암 검진 시장

About Author:

Ravina Pandya, Content Writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc.

(https://www.linkedin.com/in/ravina-pandya-1a3984191)